uniQure (NASDAQ:QURE) Stock Rating Lowered by Royal Bank Of Canada

uniQure (NASDAQ:QURE) was downgraded by Royal Bank Of Canada from a “moderate buy” rating to a “hold” rating in a research note issued to investors on Monday, MarketBeat Ratings reports. They currently have a $11.00 price objective on the biotechnology company’s stock. Royal Bank Of Canada’s target price would indicate a potential upside of 21.82% from the company’s current price.

Other equities research analysts have also issued reports about the stock. William Blair reissued a “market perform” rating on shares of uniQure in a report on Tuesday, November 11th. Barclays began coverage on uniQure in a research report on Tuesday, January 27th. They set an “equal weight” rating and a $31.00 price target for the company. Leerink Partners dropped their price target on uniQure from $68.00 to $60.00 and set an “outperform” rating on the stock in a research note on Monday, November 10th. Wolfe Research initiated coverage on uniQure in a research note on Monday, February 23rd. They issued a “peer perform” rating for the company. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating and set a $9.00 target price (down from $55.00) on shares of uniQure in a report on Monday. Seven investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $34.33.

uniQure Stock Performance

QURE opened at $9.03 on Monday. The company has a market cap of $562.48 million, a P/E ratio of -2.62 and a beta of 0.73. The company has a quick ratio of 7.12, a current ratio of 7.12 and a debt-to-equity ratio of 0.23. The firm’s 50-day moving average price is $22.86 and its 200-day moving average price is $29.72. uniQure has a 52-week low of $7.76 and a 52-week high of $71.50.

uniQure (NASDAQ:QURE) last released its earnings results on Monday, March 2nd. The biotechnology company reported ($0.56) earnings per share for the quarter, topping the consensus estimate of ($0.93) by $0.37. uniQure had a negative net margin of 1,236.00% and a negative return on equity of 230.98%. The company had revenue of $5.57 million for the quarter, compared to the consensus estimate of $4.84 million. As a group, equities analysts anticipate that uniQure will post -3.75 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CFO Christian Klemt sold 6,217 shares of the company’s stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $23.86, for a total value of $148,337.62. Following the sale, the chief financial officer owned 211,513 shares in the company, valued at $5,046,700.18. This represents a 2.86% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Matthew C. Kapusta sold 12,378 shares of uniQure stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $23.86, for a total value of $295,339.08. Following the transaction, the chief executive officer owned 639,076 shares of the company’s stock, valued at approximately $15,248,353.36. This represents a 1.90% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 50,598 shares of company stock worth $1,248,588 over the last ninety days. 4.79% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On uniQure

Several institutional investors have recently made changes to their positions in QURE. Seven Fleet Capital Management LP purchased a new stake in uniQure during the fourth quarter worth $209,000. Virtus Investment Advisers LLC increased its holdings in uniQure by 91.6% in the fourth quarter. Virtus Investment Advisers LLC now owns 13,636 shares of the biotechnology company’s stock valued at $326,000 after buying an additional 6,520 shares in the last quarter. SummitTX Capital L.P. raised its position in shares of uniQure by 386.3% in the fourth quarter. SummitTX Capital L.P. now owns 27,708 shares of the biotechnology company’s stock worth $663,000 after acquiring an additional 22,010 shares during the period. Suvretta Capital Management LLC acquired a new position in shares of uniQure in the fourth quarter worth about $29,116,000. Finally, Readystate Asset Management LP purchased a new stake in shares of uniQure during the 4th quarter worth about $8,652,000. 78.83% of the stock is owned by hedge funds and other institutional investors.

More uniQure News

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: Q4 results beat the EPS consensus (reported loss narrower than expected) and revenue slightly exceeded estimates — provides near‑term financial relief but did not offset regulatory concerns. Q4 press release
• Positive Sentiment: Some analysts remain constructive after repricing: Chardan retained a “buy” rating (lowered PT) and Wells Fargo kept an “equal weight” stance, which could support buyer interest if worries ease. Analyst notes
• Neutral Sentiment: uniQure says it held a Type A meeting with the FDA, is evaluating Phase‑III plans for AMT‑130 and intends to request a follow‑up Type B meeting in Q2 — this signals a defined regulatory path but will likely take time and resources. Company update
• Neutral Sentiment: Corporate disclosure flagged a governance risk tied to a 2026 shift to the Dutch “large company” regime — a longer‑term structural governance change that bears monitoring but is not an immediate earnings driver. TipRanks note
• Negative Sentiment: Regulatory blow: the FDA told uniQure its early‑stage AMT‑130 data are insufficient for a marketing application and has recommended a randomized, sham‑controlled Phase III study — a materially more onerous and time‑consuming path that triggered the sharp market selloff. Reuters: FDA tells UniQure
• Negative Sentiment: Analysts slashed price targets and ratings after the FDA decision (Goldman lowered its PT to $9 and moved to neutral; Cantor, RBC, Mizuho and others also cut PTs or ratings) — analyst repricing removes supporting buy‑side momentum and amplifies downside risk. Analyst coverage changes
• Negative Sentiment: Multiple law firms have filed or are soliciting plaintiffs for securities class actions tied to the company’s disclosures during a defined class period — increased legal risk, potential settlements or litigation costs add uncertainty for shareholders. Rosen Law Firm notice
• Negative Sentiment: Market reaction: heavy volume and steep price declines since the FDA announcement reflect rapid repricing of AMT‑130’s value and higher execution risk for the company’s lead gene‑therapy program. Bloomberg coverage

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.